Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Mostrar otras versiones (1)

BACKGROUND: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven. OBJECTIVES: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with surgically unsalvageable giant cell tumor of bone. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shenglong, Chen, Peng, Yang, Qiankun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357891/
https://www.ncbi.nlm.nih.gov/pubmed/30740297
http://dx.doi.org/10.1016/j.jbo.2019.100217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357891/
https://www.ncbi.nlm.nih.gov/pubmed/30740297
http://dx.doi.org/10.1016/j.jbo.2019.100217

Ejemplares similares